UPDATE: JP Morgan Raises PT to $62 on Health Care REIT Post Q2
JP Morgan reiterated its Overweight rating on Health Care REIT (NYSE: HCN) and increased its price target from $61 to $62.
JP Morgan commented, "Our OW rating on HCN is based on a number of factors including our belief that the stock has above-average growth prospects relative to the health care sector, and we see valuation attractive based on discounted trading multiples and an above-average dividend yield."
Health Care REIT closed at $60.17 on Thursday.
Latest Ratings for HCN
|Jan 2017||SunTrust Robinson Humphrey||Downgrades||Buy||Hold|
|Jan 2017||Mitsubishi UFJ||Upgrades||Neutral||Overweight|
|Dec 2016||Wells Fargo||Downgrades||Outperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.